Navigation Links
AFRESA(R) Phase 3 Pulmonary Function Safety Data in Patients with Diabetes Presented at ADA
Date:6/6/2009

Two-year study presented at the American Diabetes Association's 69th Scientific Sessions shows investigational product comparable to standard insulin therapy in pulmonary function tests

NEW ORLEANS, June 6 /PRNewswire-FirstCall/ -- AFRESA(R) (insulin human [rDNA origin]) Inhalation Powder is a well-tolerated, ultra rapid acting insulin with changes in pulmonary function tests comparable to usual antidiabetic treatment, according to data presented today at the American Diabetes Association's 69th Scientific Sessions. Results from the prospective, multicenter, phase 3 study conducted over a two-year period showed no difference in mean change in forced expiratory volume in one second (FEV(1)) between those treated with AFRESA and those treated with standard insulin therapy.

"Current mealtime insulin therapies, while accepted as an effective means to control glucose levels, have several limitations," said Peter Richardson, Corporate Vice President and Chief Scientific Officer, MannKind Corporation. "Our encouraging findings indicate that AFRESA may be a promising new treatment option with less weight gain and lower risk of hypoglycemia compared with current mealtime insulin therapy."

AFRESA is a novel, ultra rapid acting mealtime insulin therapy with an action profile that mimics meal-related early insulin release. Based on an extensive phase 3 clinical program, a New Drug Application (NDA) has been accepted by the U.S. Food and Drug Administration (FDA) requesting approval to market AFRESA Inhalation Powder and the AFRESA Inhaler for use in adult patients with type 1 and type 2 diabetes mellitus for the treatment of hyperglycemia. AFRESA is conveniently administered by oral inhalation.

Diabetes, which affects 23.6 million people in the U.S., or 8 percent of the population, is characterized by the body's inability to properly regulate levels of blood glucose, or blood sugar. Insulin, a hormone
'/>"/>

SOURCE MannKind Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials
2. PARI Pharma Reports Successful Phase Ib Clinical Results for Inhaled Liposomal Cyclosporine A and Gains FDA Orphan Drug Designation for the Prevention and Treatment of Bronchiolitis Obliterans
3. Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients
4. Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Associations 69th Scientific Sessions
5. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
6. Neurobiological Technologies Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program
7. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
8. Trubion Announces Positive Data From a Phase 1 / 2 Study of TRU-016 for the Treatment of Chronic Lymphocytic Leukemia (CLL)
9. Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
10. TNFerade(TM) Phase III Data Presented at ASCO
11. Ironwood and Forest Present Additional Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... y PARÍS, 24 de mayo de 2013 /PRNewswire/ ... destacado desarrollador y fabricante de herramientas de precisión ... y tratamiento de la enfermedad vascular periférica y ... ADVISE ( Ad enosine V asodilator ... II durante la sesión de ensayo clínico hot ...
(Date:5/23/2013)... , May 23, 2013 Amgen (NASDAQ: ... Annual  Healthcare Conference on Thursday, May 30, 2013, at ... beginning at 9:20 a.m. Eastern Daylight Time. Arvind ... will present at the conference. Live audio of the presentation ... www.amgen.com , under Investors. A replay of the webcast ...
(Date:5/23/2013)... , May 23, 2013 Nephros, Inc. ... stage medical device company that develops and sells high ... of its rights offering.  In addition, the concurrent temporary ... warrants expired on May 17, 2013. Nephros ... million from the rights offering.   A portion of the ...
Breaking Medicine Technology:Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6Nephros Announces Completion of Rights Offering 2Nephros Announces Completion of Rights Offering 3Nephros Announces Completion of Rights Offering 4
... China, April 16, 2011 China Medical Equipment ... provider of ultrasound and MRI systems in China, ... portable ultrasound machine. The iuStar100 utilizes Samplify,s high-performance, ... SAM1600 analog to digital converter (ADC) to deliver ...
... Md., April 15, 2011 The U.S. Food and ... or in combination with methotrexate, for the treatment ... children ages 2 years and older. ... Still,s disease, is a rare, potentially life-threatening disorder ...
Cached Medicine Technology:United Imaging Healthcare Leverages Samplify's Analog Front-End Solutions to Deliver New Portable Ultrasound System with Superior Image Quality 2FDA Approves Actemra to Treat Rare Form of Juvenile Arthritis 2FDA Approves Actemra to Treat Rare Form of Juvenile Arthritis 3
(Date:5/24/2013)... Beach, Delaware (PRWEB) May 24, 2013 ... Mushrush has joined the Dayna Feher team at the ... Mushrush made the Delaware resorts her home in 1975. ... has since worked in all aspects of the real ... and for the past 12 years, a licensed sales ...
(Date:5/24/2013)... With Memorial Day Weekend upon us, cookout ... is offering tips to help prevent grill fires throughout the ... (NFPA) reports that gas grills led to an average ... other solid-fueled grills, meanwhile, caused approximately 1,200 home fires per ... Insurance is sharing the following tips from the NFPA to ...
(Date:5/24/2013)... -- New research suggests a link between sleep ... Every additional hour someone with insomnia sleeps ... the likelihood of moderate or high risk of ... Pennsylvania. "We were surprised by the ... suicide risk," study author, Linden Oliver, clinical research ...
(Date:5/24/2013)... Calif.) (PRWEB) May 24, 2013 ... House Appropriators and the California congressional delegation, joined ... restore sequestered industry user fees paid to the ... to ensure that future across-the-board cuts will not ... of the FY14 Agriculture, Rural Development and FDA ...
(Date:5/24/2013)... -- Drugs commonly used to treat glaucoma may cause ... with vision, according to a new study. The ... to reduce eye pressure, have already been shown to ... the researchers said, suggesting that the new findings could ... should be conservative when prescribing these drugs, the researchers ...
Breaking Medicine News(10 mins):Health News:Tammy Mushrush Joins ResortQuest Real Estate® and the Dayna Feher Team 2Health News:Don’t Get Burned: Five Grilling Tips from Amica Insurance 2Health News:Sleep Duration Linked to Suicidal Thoughts in People With Insomnia 2Health News:California Biomedical Industry Leaders Urge Congress to Take Action on FDA User Fees for FY2014 2Health News:California Biomedical Industry Leaders Urge Congress to Take Action on FDA User Fees for FY2014 3Health News:Common Glaucoma Drug May Cause Droopy Eyelids, Study Finds 2
... Safest, Most Fuel-Efficient Route and Protect Sensitive Medical Equipment as They Bring ... ... Calif. (Vocus) March 16, 2009 -- Applied Weather Technology (AWT) ... ships to deliver free, world-class health care services to the poor, recently ...
... faster by automating the admissions process with Web-based referral management software ... ... GA (PRWEB) March 16, 2009--Patient Placement System announced today the launch ... The Web-based service is an easy, low-cost software solution ...
... SHENZHEN, China, March 16 /PRNewswire-Aisia-FirstCall/ -- China Nepstar,Chain ... Nepstar" or the "Company"), the,largest drugstore chain in ... today announced that the Board of Directors has ... Share (ADS), or approximately,RMB250 million, which amounts to ...
... follows brain injury, researcher says, , , SUNDAY, March 15 ... drugs may prevent long-term damage from traumatic brain injury, ... Center researchers. , The drugs -- gamma-secretase inhibitors -- ... the brains of people with Alzheimer,s disease, according to ...
... carefully administered daily dose of peanuts has been so successful ... of children is now off treatment and eating peanuts daily, ... Hospital. , "It appears these children have lost their ... Pediatric Allergy and Immunology at Duke. "This gives other parents ...
... better than Lasik for individuals over 50. It Imparts distance and near ... cataracts, and does not induce dry eye. , ... Los Angeles, CA ... is better than Lasik for individuals over 50. It Imparts distance and ...
Cached Medicine News:Health News:Applied Weather Technology Guides Mercy Ships with Latest BVS Marine Voyage Optimization Software 2Health News:Applied Weather Technology Guides Mercy Ships with Latest BVS Marine Voyage Optimization Software 3Health News:Applied Weather Technology Guides Mercy Ships with Latest BVS Marine Voyage Optimization Software 4Health News:Applied Weather Technology Guides Mercy Ships with Latest BVS Marine Voyage Optimization Software 5Health News:Patient Placement Systems Announces Free 30-Day Trial Program for Referral Management System 2Health News:Patient Placement Systems Announces Free 30-Day Trial Program for Referral Management System 3Health News:China Nepstar Chain Drugstore Announces Dividend 2Health News:China Nepstar Chain Drugstore Announces Dividend 3Health News:Alzheimer's Drug May Someday Help Head Trauma Victims 2Health News:Studies show children can complete treatment for peanut allergies and achieve long-term tolerance 2Health News:Studies show children can complete treatment for peanut allergies and achieve long-term tolerance 3Health News:PRELEX is the Answer for Baby Boomers Vision Needs 2
... Biosensor's compact BioStress 2000 is a software ... Stress testing system. The BioStress 2000 program ... ECG viewing, permanent ECG strorage and retrieval ... any printer. BioStress 2000 allows a wide ...
Part of the Octopus System which includes both the Starfish & Octopus3. The Octopus3 Tissue Stabilizer is the pioneering and market-leading suction device....
... a simple way to lift the heart ... the XPOSE 3. The XPOSE 3 is ... off-pump bypass surgery and to easily position ... Designed for both apical and non-apical placement ...
... The CLEARGLIDE Optical Vessel Dissector has ... an operative cavity in the extraperitoneal spaces ... areas. The device may be used in ... The EVH system enables harvesting of a ...
Medicine Products: